This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia
by Zacks Equity Research
The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.
Top Ranked Income Stocks to Buy for March 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 26th.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $67.91, moving +0.62% from the previous trading session.
Coronavirus Drug Development Race to Boost These 4 Stocks
by Zacks Equity Research
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy
by Zacks Equity Research
CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.
The Extreme Risks of Trading Your Own Retirement Assets - March 25, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - March 24, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive AML patients.
Roche Gets FDA Approval for Actemra Trials in COVID-19
by Zacks Equity Research
Roche (RHHBY) gets FDA nod to evaluate Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
Powerful Proof Anyone Can Invest for an Early Retirement - March 24, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Top Ranked Income Stocks to Buy for March 24th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 24th.
Is AbbVie a Good Stock to Buy Amid Coronavirus Uncertainty?
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
4 Dividend Stocks to Buy Amid the Coronavirus Rout
by Nitish Marwah
The coronavirus has dealt a huge blow to markets globally. Valuations have gone for a toss across every asset class and sector.
AbbVie Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AbbVie has been struggling lately, but the selling pressure may be coming to an end soon.
Is AbbVie (ABBV) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.
What Makes AbbVie (ABBV) a New Buy Stock
by Zacks Equity Research
AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Merck's Chronic Cough Candidate Achieves Goals in Phase III
by Zacks Equity Research
Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.
Johnson & Johnson (JNJ) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Johnson & Johnson (JNJ) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - March 18, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - March 18, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $72.99, marking a -1.72% move from the previous day.
How Trading Your Own Retirement Can Fleece Your Financial Future - March 17, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
AbbVie (ABBV) Jumps: Stock Rises 8.6%
by Zacks Equity Research
AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.